To investigate the safety, tolerability, PD, and PK of BI 3802876
when administered intravenously in single rising doses following
MABEL dose administration in adult patients with compensated
cirrhosis due to MASH.

This study will enroll patients that were either diagnosed with hepatocellular cancer (HCC) in the past 6 weeks or have been diagnosed with cirrhosis but do not have HCC. Patients will have a blood sample collected to test if a new blood-based biomarker is accurate in the early detectection of HCC.

To evaluate if daily oral administration of elafibranor 120 mg improves the time of event free survival compared to placebo in adults with Primary Sclerosing Cholangitis (PSC).

The aim of this study is to assess the efficacy and safety of an investigational medication, Inebilizumab, in patients with autoimmune hepatitis (AIH) who inadequately respond to at least 9 months of standard-of-care (SOC) treatment, or who are intolerant to SOC within 6 months of screening.

This study is investigating how efimosfermin, compared to a placebo, might improve liver fibrosis in patients with biopsy-proven stage F2- or F3 Metabolic Dysfunction-Associated Steatohepatitis (MASH), also known as "fatty liver disease".

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

This study will examine how medications called GLP-1 receptor agonists should be managed before an upper endoscopy. Participants taking a weekly GLP-1 receptor agonist will be randomly assigned to continue their medication, stop it for 7 days before the procedure, or stop it for 14 days before the procedure. Before the endoscopy, an ultrasound will be used to assess the amount and type of contents remaining in the stomach. The study will compare the groups to determine how different medication hold times affect the amount of stomach contents present at the time of endoscopy. The results may help inform future recommendations for managing GLP-1 receptor agonists before endoscopic procedures.